

CHANGE OF REGISTERED OFFICE

PERTH, Australia and SAN FRANCISCO, California – 26 February 2024

In accordance with ASX Listing Rule 3.14, PYC Therapeutics Limited ('PYC' or the 'Company') (ASX: PYC) advises that the Company's registered office has changed to:

Office 4, Level 1
174 Hampden Road
NEDLANDS WA 6009

Telephone: +61 8 6151 0992

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials. PYC is progressing two more drug candidates with disease-modifying potential into human studies in 2024².

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

² Management forecast as of February 2024. Progression of the drug candidate on these timelines is subject to ongoing success of the development program and includes all risks customary to an early-stage biotechnology company including regulatory risks.